Press releases
- Devonian Health Group Reports Second Quarter 2024 Financial Results and Business Update
- Devonian Announces Closing of a Private Placement of Units
- Devonian Names Kathryn J. Gregory to the Board of Directors and Grants Stock Options
- Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada
- Devonian Announces a $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan
- Devonian Announces the Results of its Annual General and Special Shareholders' Meeting, the Approval of Amendments to its Stock Option Plan, and Grant of Stock Options
- Devonian Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease
More ▼
Key statistics
On Thursday, Devonian Health Group Inc (GSD:CVE) closed at 0.22, -25.42% below its 52-week high of 0.295, set on Apr 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | 0.215 |
Offer | 0.25 |
Previous close | 0.22 |
Average volume | 2.00k |
---|---|
Shares outstanding | 148.22m |
Free float | 127.17m |
P/E (TTM) | -- |
Market cap | 32.60m CAD |
EPS (TTM) | -0.0304 CAD |
Data delayed at least 15 minutes, as of Apr 18 2024.
More ▼